Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer

被引：28

作者：

Garofalo, Antonio ^{[1
]}

Goossens, Laurence ^{[1
]}

Lemoine, Amelie ^{[1
]}

Farce, Amaury ^{[1
]}

Arlot, Yannick ^{[2
]}

Depreux, Patrick ^{[1
]}

机构：

[1] Univ Lille Nord France, Inst Chim Pharmaceut Albert Lespagnol, F-59006 Lille, France

[2] Univ Rennes 1, CNRS, UMR 6061, Rennes, France

来源：

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY | 2010年 / 25卷 / 02期

关键词：

Quinazoline; EGFR; VEGFR; inhibitors; cancer; prostate; TYROSINE KINASES; TUMOR-GROWTH; ANDROGEN RECEPTOR; POTENT; THERAPY; TARGETS; CELLS; IDENTIFICATION; VALIDATION; ANGIOGENESIS;

D O I：

10.3109/14756360903169485

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor-2 (VEGFR-2), two protein tyrosine kinases, are involved in pathological disorders and the progression of different types of carcinomas. Concomitant inhibition of both tyrosine kinase activities appears to be an attractive target for cancer chemotherapy. A series of new quinazoline derivatives substituted by amide, urea, or carbamic acid ester groups have been synthesized. The biological activities of these new compounds have been evaluated for their enzyme inhibition and antiproliferative activities.</.

引用

页码：158 / 171

页数：14

共 42 条

[1] Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells [J].

Amin, Dhara N. ;

Bielenberg, Diane R. ;

Lifshits, Eugene ;

Heymach, John V. ;

Klagsbrun, Michael .

MICROVASCULAR RESEARCH, 2008, 76 (01) :15-22

[2]

BARBER HJ, 1961, J CHEM SOC, V28, P28

[3] Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer [J].

Barker, AJ ;

Gibson, KH ;

Grundy, W ;

Godfrey, AA ;

Barlow, JJ ;

Healy, MP ;

Woodburn, JR ;

Ashton, SE ;

Curry, BJ ;

Scarlett, L ;

Henthorn, L ;

Richards, L .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (14) :1911-1914

[4] Growth factors and their receptors: New targets for prostate cancer therapy [J].

Barton, J ;

Blackledge, G ;

Wakeling, A .

UROLOGY, 2001, 58 (2A) :114-122

[5] The Protein Data Bank [J].

Berman, HM ;

Westbrook, J ;

Feng, Z ;

Gilliland, G ;

Bhat, TN ;

Weissig, H ;

Shindyalov, IN ;

Bourne, PE .

NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242

[6] Androgen receptor signalling in prostate: Effects of stromal factors on normal and cancer stem cells [J].

Berry, Paul A. ;

Maitland, Norman J. ;

Collins, Anne T. .

MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2008, 288 (1-2) :30-37

[7]

Bouey-Bencteux E, 1998, ANTI-CANCER DRUG DES, V13, P893

[8] Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy [J].

Ciardiello, F ;

Bianco, R ;

Caputo, R ;

Damiano, V ;

Troiani, T ;

Melisi, D ;

De Vita, F ;

De Placido, S ;

Bianco, AR ;

Tortora, G .

CLINICAL CANCER RESEARCH, 2004, 10 (02) :784-793

[9] VALIDATION OF THE GENERAL-PURPOSE TRIPOS 5.2 FORCE-FIELD [J].

CLARK, M ;

CRAMER, RD ;

VANOPDENBOSCH, N .

JOURNAL OF COMPUTATIONAL CHEMISTRY, 1989, 10 (08) :982-1012

[10] The role of protein phosphorylation in human health and disease - Delivered on June 30th 2001 at the FEBS Meeting in Lisbon [J].

Cohen, P .

EUROPEAN JOURNAL OF BIOCHEMISTRY, 2001, 268 (19) :5001-5010

← 1 2 3 4 5 →